Opinion

Video

The Role of ADT in Localized or Locally Advanced Prostate Cancer

Author(s):

Lawrence Karsh, MD, FACS,Stephen J. Freedland, MD

3. Terence Friedlander, MD, provides clinical insights on factors that inform the role for androgen deprivation therapy in the treatment of patients with localized or locally advanced prostate cancer.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Expert discusses differentiating prostate cancer from age-related issues
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
Ruben Olivares, MD, answers a question during a Zoom video interview
Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Strategies to bridge gender disparities in AAS and citations in the oncology literature
Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
1 expert in this video
Selecting Between Receptor Pathway Inhibitors for mHSPC
1 expert in this video
The Use of Ultra-Low PSA in Specific Patient Profiles
Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
Related Content
FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
June 20th 2025

FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

Hannah Clarke
The phase 1 study is set to begin later this year.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Real-world studies compare overall survival between ARPIs in mCSPC
June 19th 2025

Real-world studies compare overall survival between ARPIs in mCSPC

Mehmet Asim Bilen, MD Hannah Clarke
"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke
ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
June 17th 2025

FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC

Hannah Clarke
Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
© 2025 MJH Life Sciences

All rights reserved.